Marc-Oliver Grimm, Martin Schostak, Christine Barbara Grün, Wolfgang Loidl, Martin Pichler, Uwe Zimmermann, Bernd Schmitz-Dräger, Thomas Steiner, Florian Roghmann, Günter Niegisch, Christian Bolenz, Marc Schmitz, Gustavo Baretton, Katharina Leucht, Ulrike Schumacher, Susan Foller, Friedemann Zengerling, Johannes Meran
IMPORTANCE: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes with added high-dose ipilimumab. OBJECTIVE: To assess efficacy and safety of a tailored approach using nivolumab + ipilimumab as an immunotherapeutic boost for mUC. DESIGN, SETTING, AND PARTICIPANTS: In this phase 2 nonrandomized trial, patients with mUC composed 2 cohorts...
May 9, 2024: JAMA Oncology